Stock 600062 CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News China Resources Double-Crane Pharmaceutical Co.,Ltd.

Equities

600062

CNE000000Q94

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
23.57 CNY +1.16% Intraday chart for China Resources Double-Crane Pharmaceutical Co.,Ltd. +8.27% +26.72%
08/05 CR Double-Crane Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride Injection MT
26/04 CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CR Double-Crane Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride Injection
MT
CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2%
MT
CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication
MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
CR Double-Crane Pharmaceutical Gets Nod to Trial Semaglutide Injection
MT
CR Double-Crane Pharma Unit Receives Approval for Epilepsy Drug
MT
CR Double-Crane Pharma's 2023 Profit Jumps 13%, Operating Income Climbs 6%
MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. Proposes Cash Dividend
CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CR Double-crane Pharmaceutical Gets Nod to Market Doxazosin Mesylate Tablets
MT
China Resources Double-Crane Pharmaceutical Co.,Ltd. agreed to acquire China Resources Zizhu Pharmaceutical Co., Ltd. from Beijing Pharmaceutical Group Co., Ltd. for CNY3.1 billion.
CI
CR Double-Crane Pharma Gets Nod for Apixaban Tablets; Unit's Clozapine Orally Disintegrating Tablets Gets Greenlight for Proposed Amendments
MT
CR Double-Crane Pharma's Unit Gets Nod to Market Lithium Carbonate Drug Ingredient
MT
CR Double-Crane Pharmaceutical's Unit Gets Nod to Raise Strength of Viagra Drug
MT
China Includes CR Double-Crane Pharmaceutical's Two Drugs in List of Insurance-Backed Drugs
MT
CR Double-Crane Pharma Unit Gets Nod to Amend Sodium Lactate Ringer Injection's Details
MT
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from Shanghai Stock Exchange 180 Value Index
CI
China Resources Double-Crane Pharmaceutical Co.,Ltd.(SHSE:600062) dropped from SSE 180 Index
CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acqyusution 89.681% stake in Guizhou Tianan Pharmaceutical Company from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd.
CI
China Resources Double-Crane Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600062 Stock
  4. News China Resources Double-Crane Pharmaceutical Co.,Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW